MPR Kontakt Icon
Choose language
MPR Suche
MPR Close

Ebola vaccine wins approval from China Food and Drug Administration

28. November 2017

According to the official Chinese news agency Xinhua, medical company, Tianjin CanSino Biotechnology is investing around 2 billion yuan to build a major medical facility in Tianjin to produce a revolutionary Ebola vaccine.

Notably, this makes China the third country, along with the USA and Russia, with vaccines ready to combat Ebola.

The vaccine, which was developed in conjunction with the Chinese military and was approved by the China Food and Drug Administration (CFDA), who are responsible for food safety, drugs, medical devices and cosmetics, has been developed as a response to the West African Ebola Epidemic that tragically led to the death of around 11,000 people.

Ebola virus

Tianjin CanSino Biotechnology started trials last year and intend on having the new facility up and running by 2018 and hope it will challenge current global Ebola vaccination leaders Merck and NewLink Genetics. Though a production date has yet to be set.

Currently Merck and NewLink Genetics vaccine comes in liquid form, Tianjin CanSino Biotechnology will be available in powder form, which the firm claim will be a far better solution because it can be more easily transported and used in harsher tropical climates.

Please do not hesitate to contact us for further details and consultation. You can contact us via e-mail, or call us (UK: +44 2071931135, Rest of Europe: +49 69 2713769150, US: +1 773 654-2673).

MPR Author

About the author: Julian Busch is founder and managing director of MPR China Certification GmbH
Publisher: MPR China Certification GmbH

Tel.: +49 69 271 37 69 150